Best Practice & Research Clinical Rheumatology
Volume 22, Issue 1 , Pages 45-54 , March 2008

Hereditary multiple exostoses and enchondromatosis

References 

  1. Solomon L. Hereditary multiple exostoses. The Journal of Bone and Joint Surgery. 1963;A45:292–304
  2. Schmale GA, Conrad EU, Rasking WH. The natural history of hereditary multiple exostoses. The Journal of Bone and Joint Surgery. 1994;A76:986–992
  3. Legeai-Mallet L, Munnich A, Maroteaux P, Le Merrer M. Incomplete penetrance and expressivity skewing in hereditary multiple exostoses. Clinical Genetics. 1997;52:12–16
  4. Ollier M. Dyschondroplasie. Lyon Medical. 1990;93:23–25
  5. Olsen RO, Reginato AM, Wang W. Bone development. Annual Review of Cell and Developmental Biology. 2000;16:191–220
  6. Jaffe HL. Tumors and Tumorous Conditions of the Bones and Joints. Philadelphia: Lea and Febiger; 1968;
  7. Robbins SE, Laitt RD, Lewis T. Hereditary spinal osteochondromas in diaphyseal aclasia. Neuroradiology. 1996;38:59–61
  8. Cook A, Rasking W, Blandon SH, et al. Genetic heterogeneity in families with hereditary multiple exostoses. American Journal of Human Genetics. 1993;53:71–79
  9. Wu YQ, Heutink P, de Vries BB, et al. Assignment of a second locus for multiple exostoses to the pericentromeric region of chromosome 11. Human Molecular Genetics. 1994;3:167–171
  10. Le Merrer M, Legeai Mallet L, Jeannin P, et al. A gene for hereditary multiple exostoses map to chromosome 19p. Human Molecular Genetics. 1994;3:717–722
  11. Rasking WH, Conrad EU, Chansky H, Matsushita M. Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. American Journal of Human Genetics. 1998;56:1125–1131
  12. Hecht JT, Hogue D, Wang Y, et al. Hereditary multiple exostoses (EXT): mutational studies of familial EXT1 cases and EXT-associated malignancies. American Journal of Human Genetics. 1997;60:80–86
  13. Ahn I, Ludecke HJ, Lindow S, et al. Cloning of the putative tumor suppressor gene for hereditary multiple exostoses (EXT1). Nature Genetics. 1995;11:137–143
  14. Wuyts W, Van Hul W, Waunters J, et al. Positional cloning of a gene involved in hereditary multiple exostoses. Human Molecular Genetics. 1996;10:1547–1557
  15. McCormick C, Leduc Y, Martindale D, et al. The putative tumor suppressor EXT1 alters the expression of heparan sulfate. Nature Genetics. 1998;19:158–161
  16. Lind T, Tufaro F, McCormick C, et al. The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. The Journal of Biological Chemistry. 1998;273:26265–26268
  17. Duncan G, McCormick C, Tufaro F. The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative suppressor tumor proteins. The Journal of Clinical Investigation. 2001;108:511–516
  18. Wuyts W, Van Hul W, De Boulle K, et al. Mutations in the EXT1 and EXT2 genes in hereditary multiple exostoses. American Journal of Human Genetics. 1998;62:346–354
  19. Seki H, Kubota T, Ikegawa S, et al. Mutation frequencies of EXT1 and EXT2 in 43 Japanese families with hereditary multiple exostoses. American Journal of Medical Genetics. 2001;99:59–62
  20. Francannet C, Cohen-Tanugi A, Le Merrer M, et al. Genotype-phenotype correlation in hereditary multiple exostoses. Journal of Medical Genetics. 2001;38:430–434
  21. Pedrini E, De Luca A, Valente EM, et al. Novel EXT1 and EXT2 mutations identified by DHPLC in Italian patients with multiple osteochondromas. Human Mutation. 2005;26:280
  22. Lonie L, Porter DE, Fraser M, et al. Determination of the mutation spectrum of the EXT1/EXT2 genes in British Caucasian patients with multiple osteochondromas, and exclusion of six candidate genes in EXT negative cases. Human Mutation. 2006;27:1160
  23. Signori E, Massi E, Matera MG, et al. Combined analytical approach reveals novel EXT1/2 gene mutations in a large cohort of Italian multiple osteochondromas patients. Genes Chromosomes and Cancer. 2007;46:470–477
  24. Porter DE, Lonie L, Fraser M, et al. Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study. The Journal of Bone and Joint Surgery. British Volume. 2004;86:1041–1046
  25. Silve C, Juppner H. Ollier disease. Orphanet Journal of Rare Diseases. 2006;1:37
  26. Maffucci A. Di un caso encondroma ed angioma multiplo. Movimento Medico-Chirurgico Napoli. 1881;3:399–412
  27. Gabos PG, Bowen JR. Epiphyseal-metaphyseal enchondromatosis. A new clinical entity. The Journal of Bone and Joint Surgery. American Volume. 1998;80:782–792
  28. Bovee JV, Graadt van Roggen JF, Cleton-Jansen AM, et al. Malignant progression in multiple enchondromatosis (Ollier's disease): an autopsy-based molecular genetic study. Human Pathology. 2000;31:1299–1303
  29. Ozisik YY, Meloni AM, Spanier SS, et al. Deletion 1p in a low-grade chondrosarcoma in a patient with Ollier disease. Cancer Genetics and Cytogenetics. 1998;105:128–133
  30. Hopyan S, Gokgoz N, Poon R, et al. A mutant PTH/PTHrP type I receptor in enchondromatosis. Nature Genetics. 2002;30:306–310
  31. Rozeman LB, Sangiorgi L, Briaire-de Bruijn IH, et al. Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the PTHR1 mutation p.R150C. Human Mutation. 2004;24:466–473
  32. Stickens D, Beverly M, Rougier N, et al. Mice deficient in EXT2 lack heparan sulfate and develop exostoses. Development. 2006;132:5055–5068

PII: S1521-6942(07)00137-4

doi: 10.1016/j.berh.2007.12.004

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 1 , Pages 45-54 , March 2008

Article Tools

* Image Usage & Resolution